Efficacy and tolerability of acetazolamide in migraine prophylaxis: A randomised placebo-controlled trial

Journal of Neurology

Volumn 249, Issue 2, 2002, Pages 206-211

  Vahedi, K ^a   Taupin, P ^b   Djomby, R ^a   El Amrani, M ^a   Lutz, G ^a   Filipetti, V ^c   Landais, P ^b   Massiou, H ^a   Bousser, M G ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Acetazolamide; Migraine; Prophylaxis

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE;

ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036167182     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007866     Document Type: Article

References (24)

1. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4
2. Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia
3. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine
4. Genetic heterogeneity in Italian families with familial hemiplegic migraine
5. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2
6. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel
7. A gene for hereditary paroxysmal cerebellar ataxia maps to chromosome 19p
8. Hereditary paroxysmal ataxia: Response to acetazolamide
9. Effects of acetazolamide on myotonia
10. Acetazolamide responsiveness in familial hemiplegic migraine
11. A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia
12. Guidelines for controlled trials of drugs in migraine
13. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
14. Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function
15. Carbonic anydrase inhibitor side effects. Serum chemical analysis
16. Acetazolamide in the treatment of acute mountain sickness: Clinical efficacy and effect on gas exchange
17. Benign intracranial hypertension
18. A double-blind, randomised, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine
19. Migraine patients with topiramate-induced shortness of breath
20. Dopamine hypersensitivity in migraine: Role of the apomorphine test
21. Familial periodic cerebellar ataxia: A problem of cerebellar intracellular pH homeostasis
22. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy
23. Abnormalbrain and muscle energy metabolism shown by 31P-MRS in familial hemiplegic migraine